Heterogeneous Neutrophil Responses in Acute Lung Injury
急性肺损伤中的异质中性粒细胞反应
基本信息
- 批准号:6916449
- 负责人:
- 金额:$ 151.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-08-01 至 2007-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
Acute lung injury (ALI) is a major clinical problem, affecting more than 50,000 patients per year
in the United States. Recent studies have shown that the mortality of ALI remains high, generally
being greater than 30%. Acute lung injury (ALI) is characterized by the accumulation of
activated neutrophils in the lungs. However, even though pathways leading to neutrophil
activation are well known, their control mechanisms in the context of ALI are poorly understood.
We propose that phenotypic patterns exist that determine the nature of the neutrophil response
to proinflammatory stimuli, thereby contributing not only to the development of ALI, but to its
severity and persistence as well. The goal of the proposed work is to define the critical genetic
and cellular risk factors that lead to ALI in certain individuals and not others. Our hypothesis is
that a proinflammatory neutrophil phenotype is associated with increased pulmonary
inflammation, a greater likelihood of developing acute lung injury, and worse outcome from
acute lung injury. We also hypothesize that this proinflammatory neutrophil phenotype is
characterized by increased production of proinflammatory cytokines, enhanced activation of
p38 and PI3K/Akt kinases, increased NF-kB activation, and resistance to glucocorticoids. This
hypothesis will be explored by the four Projects and three Cores included in this Program. The
first Specific Aim of each Project is to define high and low inflammatory phenotypes in human
neutrophils, as defined by a) activation of PI3-K, Akt, and NF-kB (Project One); b) activation of
p38 (Project Two); c) expression of proinflammatory cytokines (Project Three); and d) resistance to steroid induced cell death and inhibition of cytokine production (Project Four). The second Specific Aim of each project is to determine if high and low inflammatory phenotypes among neutrophils, as defined in the first Specific Aim, predict a) the intensity of in vivo pulmonary inflammatory responses in humans given endotoxin into the lungs, and b) the severity of lung injury in patients at risk for or with ALI. The third Specific Aim of each project is to determine the mechanisms by which a) PI3-K, Akt, and NF-kB activation (Project One); b) p38 activation (Project Two); c) proinflammatory cytokine production (Project Three); and d) glucocorticoid resistance (Project Four) lead to proinflammatory neutrophil phenotypes. The integrated approach proposed in this PPG application will provide insight not only into cellular pathways that initiate and contribute to the severity of ALI, but also into the critical genetic, immunologic, and environmental risk factors that lead to ALI in certain individuals, but not others.
描述(由申请人提供):
急性肺损伤(ALI)是一个主要的临床问题,每年影响超过50,000例患者
在美国最近的研究表明,ALI的死亡率仍然很高,
大于30%。急性肺损伤(ALI)的特征是肺内
肺部中性粒细胞活化然而,即使导致中性粒细胞
激活是众所周知的,其在ALI的背景下的控制机制知之甚少。
我们认为,表型模式的存在,决定了中性粒细胞反应的性质
促炎性刺激,从而不仅有助于发展的ALI,但其
也是持久性和持久性。这项工作的目标是确定关键的遗传因素,
以及导致某些个体而非其他个体发生ALI的细胞风险因素。我们的假设是
促炎性中性粒细胞表型与肺动脉压升高相关,
炎症,发生急性肺损伤的可能性更大,
急性肺损伤我们还假设这种促炎中性粒细胞表型是
其特征在于促炎细胞因子的产生增加,
p38和PI 3 K/Akt激酶、增加的NF-κ B活化和对糖皮质激素的抗性。这
本计划中的四个项目和三个核心将对这一假设进行探索。的
每个项目的第一个具体目标是确定人类高和低炎症表型
中性粒细胞,定义如下:a)PI 3-K、Akt和NF-κ B的活化(Project One); B的活化
p38(项目二); c)促炎细胞因子的表达(项目三);和d)对类固醇诱导的细胞死亡的抗性和细胞因子产生的抑制(项目四)。每个项目的第二个具体目标是确定中性粒细胞中的高和低炎症表型(如第一个具体目标中所定义)是否预测a)给予肺内毒素的人体体内肺部炎症反应的强度,和B)处于ALI风险或患有ALI的患者中肺损伤的严重程度。每个项目的第三个具体目标是确定a)PI 3-K、Akt和NF-κ B激活(项目一); B激活(项目二); c)促炎细胞因子产生(项目三);和d)糖皮质激素抵抗(项目四)导致促炎中性粒细胞表型的机制。PPG申请中提出的综合方法不仅可以深入了解引发和导致ALI严重程度的细胞途径,还可以深入了解导致某些个体而非其他个体发生ALI的关键遗传、免疫和环境风险因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles anthony Dinarello其他文献
Charles anthony Dinarello的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles anthony Dinarello', 18)}}的其他基金
Molecular Mechanisms of Cytokine Induced Insulin Resistance
细胞因子诱导胰岛素抵抗的分子机制
- 批准号:
9388051 - 财政年份:2017
- 资助金额:
$ 151.31万 - 项目类别:
Role of Interleukin-18 in Acute Lung Injury
IL-18 在急性肺损伤中的作用
- 批准号:
6553928 - 财政年份:2002
- 资助金额:
$ 151.31万 - 项目类别:
Heterogeneous Neutrophil Responses in Acute Lung Injury
急性肺损伤中的异质中性粒细胞反应
- 批准号:
7095868 - 财政年份:2002
- 资助金额:
$ 151.31万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 151.31万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 151.31万 - 项目类别:














{{item.name}}会员




